

**RESPONSE**

Applicant elects, with traverse, Group X, claims 21. Claim 21 has been canceled, and replaced with claims 22-24 which are methods of using antibodies to detect the polypeptide coded for by the polynucleotide of claim 1. Support for the new claims can be found throughout the specification, e.g., Page 28, line 25-Page 30, line 30.

All the claims in the application involve related subject matter, e.g., human KSE132. A search would therefore comprise overlapping subject matter, and it would not be an undue burden on the examiner to carry out a search. "If search and examination of an entire application can be made without serious burden, the examiner *must* examine it on the merits, even though it includes claims to independent or distinct invention." (Emphasis added.) M.P.E.P. 803. Accordingly, withdrawal of the restriction is respectfully requested.

Respectfully submitted,

By: 

Richard M. Lebovitz (Reg. No. 37,067)  
OriGene Technologies, Inc.  
6 Taft Court, Suite 100  
Rockville, MD 20850

Filed: May 7, 2003